FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2566644413> ?p ?o ?g. }

• W2566644413 abstract "Ifosfamide (IFO) is an alkylating agent used in routine clinical practices for treatment of cancer for many years. As a prodrug it requires cytochrome P450 bio-activation (Giraud et al. Expert Opin.Drug Metab. Toxicol. 2010, 6, 919-938) oxidising the position C-4 leading to the formation of the 4-HO-IFO (10%) which releases of the active compound (isophosphoramide mustard) responsible for the DNA cross links. However, during high dose protocols, this bio-activation leads to the release of two toxic metabolites: i) acrolein, an urotoxic compound, concomitantly generated with the active isophosphoramide mustard and, ii) chloroacetaldehyde, a neurotoxic and nephrotoxic compound, arising from the oxidation of the side chains (Kerbusch et al. Clin Pharmacokinet. 2001, 40, 41-62) responsible for limiting side-effects. To circumvent these toxic side-effects, we have designed several pre-activated compounds by covalent binding of several O- and S-alkyl moieties on the carbon C-4 to avoid cytochrome bio-activation favoring the release of the 4-HO-IFO, control this release by the physico-chemical properties of the engrafted moiety and limit the chloroacetaldehyde release. Among these designed compounds, some showed a self assembling property leading to nano-assemblies formulation. Moreover, the in vitro evaluation of these compounds in absence of cytochrome has revealed that one of them: the geranyloxy-ifosfamide showed a greater activity under nano-assemblies (600nM) compared to the bulk form (15μM) on rhabdomyosarcoma. This interesting finding has led us to deepen our investigation of this compound to understand and explain the meaning of this increased activity. We present here the latest results obtained for this compound from additional in vitro evaluation on a wide panel of cancer cell line, internalization studies within the cell. Moreover, transmission electron microscopy imaging of this formulation allows the determination of the shape of these nano-assemblies. Previous studies regarding the release kinetic profile of 4-HO-IFO of this compound in vitro in mice plasma at 37°C showed an interesting release profile which was increased when tested as nano-assemblies compared to the bulk form. To validate this finding, a pharmacokinetic study has also been investigated compared to IFO, showing a higher release of 4-HO-IFO compound suggesting that this compound might have an increased therapeutic index. Also, in vivo studies are being carried out at different dose to evaluate the efficacy of this compound (as bulk and nano-assemblies) on rhabdomyosarcoma xenografted mice compared to IFO. These results increase acknowledge of this compound which could become a promising candidate for both oral and IV administration in a wide panel of tumors. Citation Format: Charles Skarbek, Didier Desmaele, Alain Deroussent, Lea Lesueur, Estelle Daudigeos-Dubus, Ludivine Le Dret, Michael Rivard, Thierry Martens, Gilles Vassal, Patrick Couvreur, Angelo PACI. Geranyloxy-ifosfamide: A pre-activated ifosfamide analogue showing an increased therapeutic index. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4537. doi:10.1158/1538-7445.AM2015-4537" @default.
• W2566644413 created "2017-01-06" @default.
• W2566644413 creator A5013203026 @default.
• W2566644413 creator A5013335730 @default.
• W2566644413 creator A5015763391 @default.
• W2566644413 creator A5025015052 @default.
• W2566644413 creator A5036401831 @default.
• W2566644413 creator A5048957528 @default.
• W2566644413 creator A5050630524 @default.
• W2566644413 creator A5057238270 @default.
• W2566644413 creator A5062927000 @default.
• W2566644413 creator A5067202962 @default.
• W2566644413 creator A5078174247 @default.
• W2566644413 date "2015-08-01" @default.
• W2566644413 modified "2023-09-26" @default.
• W2566644413 title "Abstract 4537: Geranyloxy-ifosfamide: A pre-activated ifosfamide analogue showing an increased therapeutic index" @default.
• W2566644413 doi "https://doi.org/10.1158/1538-7445.am2015-4537" @default.
• W2566644413 hasPublicationYear "2015" @default.
• W2566644413 type Work @default.
• W2566644413 sameAs 2566644413 @default.
• W2566644413 citedByCount "0" @default.
• W2566644413 crossrefType "proceedings-article" @default.
• W2566644413 hasAuthorship W2566644413A5013203026 @default.
• W2566644413 hasAuthorship W2566644413A5013335730 @default.
• W2566644413 hasAuthorship W2566644413A5015763391 @default.
• W2566644413 hasAuthorship W2566644413A5025015052 @default.
• W2566644413 hasAuthorship W2566644413A5036401831 @default.
• W2566644413 hasAuthorship W2566644413A5048957528 @default.
• W2566644413 hasAuthorship W2566644413A5050630524 @default.
• W2566644413 hasAuthorship W2566644413A5057238270 @default.
• W2566644413 hasAuthorship W2566644413A5062927000 @default.
• W2566644413 hasAuthorship W2566644413A5067202962 @default.
• W2566644413 hasAuthorship W2566644413A5078174247 @default.
• W2566644413 hasConcept C108215921 @default.
• W2566644413 hasConcept C141071460 @default.
• W2566644413 hasConcept C185592680 @default.
• W2566644413 hasConcept C19831878 @default.
• W2566644413 hasConcept C2776568683 @default.
• W2566644413 hasConcept C2776694085 @default.
• W2566644413 hasConcept C2777506904 @default.
• W2566644413 hasConcept C2778239845 @default.
• W2566644413 hasConcept C2780035454 @default.
• W2566644413 hasConcept C2780376820 @default.
• W2566644413 hasConcept C55493867 @default.
• W2566644413 hasConcept C71240020 @default.
• W2566644413 hasConcept C71924100 @default.
• W2566644413 hasConcept C98274493 @default.
• W2566644413 hasConceptScore W2566644413C108215921 @default.
• W2566644413 hasConceptScore W2566644413C141071460 @default.
• W2566644413 hasConceptScore W2566644413C185592680 @default.
• W2566644413 hasConceptScore W2566644413C19831878 @default.
• W2566644413 hasConceptScore W2566644413C2776568683 @default.
• W2566644413 hasConceptScore W2566644413C2776694085 @default.
• W2566644413 hasConceptScore W2566644413C2777506904 @default.
• W2566644413 hasConceptScore W2566644413C2778239845 @default.
• W2566644413 hasConceptScore W2566644413C2780035454 @default.
• W2566644413 hasConceptScore W2566644413C2780376820 @default.
• W2566644413 hasConceptScore W2566644413C55493867 @default.
• W2566644413 hasConceptScore W2566644413C71240020 @default.
• W2566644413 hasConceptScore W2566644413C71924100 @default.
• W2566644413 hasConceptScore W2566644413C98274493 @default.
• W2566644413 hasLocation W25666444131 @default.
• W2566644413 hasOpenAccess W2566644413 @default.
• W2566644413 hasPrimaryLocation W25666444131 @default.
• W2566644413 hasRelatedWork W2010492803 @default.
• W2566644413 hasRelatedWork W2017370862 @default.
• W2566644413 hasRelatedWork W2034492448 @default.
• W2566644413 hasRelatedWork W2036473077 @default.
• W2566644413 hasRelatedWork W2081266098 @default.
• W2566644413 hasRelatedWork W2157249206 @default.
• W2566644413 hasRelatedWork W2415326202 @default.
• W2566644413 hasRelatedWork W2781923024 @default.
• W2566644413 hasRelatedWork W2895793871 @default.
• W2566644413 hasRelatedWork W3041790145 @default.
• W2566644413 isParatext "false" @default.
• W2566644413 isRetracted "false" @default.
• W2566644413 magId "2566644413" @default.
• W2566644413 workType "article" @default.